We are live on ! Find out more
JB

Julian Baker Baker Bros. Advisors

AUM $20B
1-Year Est. Return 154.41%
 

Julian Baker is co-managing member of Baker Bros. Advisors, a firm renowned for deep specialization in biotechnology and life sciences. The firm is known for concentrated positions, long holding periods, and scientific diligence that goes well beyond typical generalist research. Baker Bros. filings are closely watched by healthcare investors for signals in clinical-stage and commercial biotech.

This Fund
S&P 500
This Quarter Est. Return
+18.97%
1 Year Est. Return
+154.41%
3 Year Est. Return
+448.58%
5 Year Est. Return
+670.61%
10 Year Est. Return
+4,743.65%
AUM
$26.5B
AUM Growth
+$1.52B
Cap. Flow
-$117M
Cap. Flow %
-0.44%
Top 10 Hldgs %
84.24%
Holding
133
New
14
Increased
16
Reduced
60
Closed
7

Top Buys

Rank Stock Value
1
ABCL icon
AbCellera Biologics
ABCL
+$478M
2
NVTA
Invitae Corporation
NVTA
+$181M
3
KOD icon
Kodiak Sciences
KOD
+$170M
4
RARE icon
Ultragenyx Pharmaceutical
RARE
+$52.7M
5
OPT
Opthea Limited American Depositary Shares
OPT
+$41.8M

Top Sells

Rank Stock Value
1
ONC
BeOne Medicines Ltd
ONC
+$450M
2
MYOK
MyoKardia, Inc. Common Stock
MYOK
+$410M
3
EXAS
Exact Sciences
EXAS
+$188M
4
IMMU
Immunomedics Inc
IMMU
+$20.2M
5
AMRN
Amarin Corp
AMRN
+$19.4M

Sector Composition

Rank Sector Weight
1 Healthcare 99.87%
2 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SYRE icon
51
Spyre Therapeutics
SYRE
$9.39B
$26.8M 0.1%
136,404
-38,780
-22% -$8.04M
FLGT icon
52
Fulgent Genetics
FLGT
$548M
$25.8M 0.1%
495,573
-50,616
-9% -$2.12M
ADPT icon
53
Adaptive Biotechnologies
ADPT
$4.15B
$22.5M 0.08%
379,682
-60,857
-14% -$3.14M
VSTM icon
54
Verastem
VSTM
$624M
$21.6M 0.08%
+845,337
New +$17M
MREO
55
Mereo BioPharma
MREO
$46.4M
$21.6M 0.08%
+6,030,293
New +$15.1M
ALT icon
56
Altimmune
ALT
$605M
$21.3M 0.08%
1,884,451
-322,504
-15% -$3.8M
AUPH icon
57
Aurinia Pharmaceuticals
AUPH
$2.22B
$19.5M 0.07%
1,410,064
-207,965
-13% -$3.03M
IMTX icon
58
Immatics
IMTX
$1.22B
$19.5M 0.07%
1,805,025
+803,611
+80% +$8.47M
NVAX icon
59
Novavax
NVAX
$1.47B
$18.9M 0.07%
169,706
-17,670
-9% -$1.88M
ACGN
60
DELISTED
Aceragen Inc
ACGN
$16.9M 0.06%
271,376
– –
CBAY
61
DELISTED
Cymabay Therapeutics
CBAY
$16.6M 0.06%
2,893,276
-359,266
-11% -$2.72M
XNCR icon
62
Xencor
XNCR
$2.07B
$16.1M 0.06%
369,370
-40,772
-10% -$1.69M
ALBO
63
DELISTED
Albireo Pharma Inc
ALBO
$15.5M 0.06%
412,466
-136,581
-25% -$4.97M
SGMO
64
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$13.4M 0.05%
857,339
-92,484
-10% -$1.08M
GWPH
65
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$13M 0.05%
112,897
-25,848
-19% -$2.9M
GMDA
66
DELISTED
Gamida Cell Ltd. Ordinary Shares
GMDA
$13M 0.05%
1,548,314
+914,990
+144% +$6.19M
KDNY
67
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$11.9M 0.04%
+748,693
New +$11.3M
FPRX
68
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$11.4M 0.04%
+668,000
New +$8.37M
MIRM icon
69
Mirum Pharmaceuticals
MIRM
$5.87B
$11.3M 0.04%
647,313
+94,304
+17% +$1.85M
SPRY icon
70
ARS Pharmaceuticals
SPRY
$547M
$11M 0.04%
+238,095
New +$7.95M
XENE icon
71
Xenon Pharmaceuticals
XENE
$5.88B
$10.6M 0.04%
687,386
-72,922
-10% -$853K
BLUE
72
DELISTED
bluebird bio
BLUE
$9.82M 0.04%
17,523
-1,931
-10% -$1.22M
ISEE
73
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$9.72M 0.04%
1,406,037
– –
ASMB icon
74
Assembly Biosciences
ASMB
$700M
$9.33M 0.04%
128,452
– –
ANAB icon
75
AnaptysBio
ANAB
$1.71B
$9.18M 0.03%
427,179
-60,064
-12% -$1.46M
1 2
3
4 5

Similar funds

ASRS
Arizona State Retirement System Phoenix, Arizona $19.9B AUM 44.71% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return
CWP
Capital Wealth Planning Naples, Florida $20B AUM 25.34% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return

Julian Baker's Q4 2020 Portfolio in Review

As of Q4 2020, Julian Baker held 133 positions worth $26.5B, up 6.1% from $25B the previous quarter. Its ten largest holdings account for 84% of the portfolio.

Julian Baker's Q4 2020 filing shows 14 new, 16 increased, 60 reduced and 7 closed positions. Its largest new stake was AbCellera Biologics: 10,450,180 shares worth $421M. The largest sale was BeOne Medicines Ltd, an estimated $450M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Financials.

  • Julian Baker's largest Q4 2020 buy was AbCellera Biologics: 10,450,180 shares worth $421M.
  • Julian Baker added most to Invitae Corporation in Q4 2020, an estimated $181M increase.
  • Julian Baker's biggest Q4 2020 reduction was BeOne Medicines Ltd, cutting an estimated $450M.
  • Julian Baker fully exited MyoKardia, Inc. Common Stock in Q4 2020, selling an estimated $410M.
  • Julian Baker's ten largest holdings make up 84% of its $26.5B portfolio in Q4 2020.
  • Julian Baker opened 14 new positions and closed 7 in Q4 2020.
  • Julian Baker's portfolio value rose 6.1% quarter-over-quarter to $26.5B.

Based on Baker Bros. Advisors's 13F filing for Q4 2020, filed 16 Feb 2021.